Macrocyclic hepatitis C serine protease inhibitors

Details Macrocyclic hepatitis C serine protease inhibitors Macrocyclic hepatitis C serine protease inhibitors

2004-02-06

2009-10-13

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S471000

Reexamination Certificate

active

07601709

ABSTRACT:
The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

REFERENCES:
patent: 6329379 (2001-12-01), Llinas-Brunet et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 2002/0037998 (2002-03-01), Llinas-Brunet et al.
patent: 2008/0039470 (2008-02-01), Niu et al.
patent: 1 437 362 (2004-07-01), None
patent: WO-00/09543 (2000-02-01), None
patent: WO-00/59929 (2000-10-01), None
patent: WO-03/053349 (2003-07-01), None
patent: WO-2004/072243 (2004-08-01), None
patent: WO2007001406 (2007-01-01), None
“Prodrug definition—Medical dictionary definitions of popular medical terms.” https://www.medterms.com/script/art.asp?articlekey=23992, accessed Jul. 11, 2007.
Njoroge et al. Accounts of Chemical Research, 2008, 41 (1), 50-59.
A. Spatola, “Peptide Backbone Modifications: A Structure-Activity Analysis of Peptides Containing Amide Bond Surrogates, Conformational Constraints, and Rela,” Department of Chemistry, University of Louisville, Louisville Kentucky, pp. 267-357, XP 002032461, 1982.
M. Llinàs-Brunet, et al., “Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease,” Bioorganic & Medicinal Chemistry Letters 8, (1998), pp. 1713-1718.

Affiliated with

Also associated with

Rating

Macrocyclic hepatitis C serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocyclic hepatitis C serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic hepatitis C serine protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4054693